SNDX   $16.11  3.27% Market Closed After Close 16.2499 0.87%

Syndax Pharmaceuticals Inc
Last Events:

2023-08-05 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-05 Trend Power changed from to almost flat.

2023-08-03 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-03 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-03 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-03 Trend Power changed from slow to .

2023-08-03 Trend changed from turning down to flat and down.


Current temperature: 8.92
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 14
Target Price Mean 36.50
Mean unverified/preliminary 36.50 / 36.50
Target Price Low / High 18.00 / 51.00
Median / STD DEV 36.50 / 8.42
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy ActivelyBuy ActivelyBuy
rsi ActivelyBuy ActivelyBuy Buy
macd None None None
stoch None None None
ma20 Sell Sell ActivelyBuy
ma50 None None None
ma100 Buy ActivelyBuy None
Candlestick PatternNov. 14, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US87164F1057
ceo Mr. Michael A. Metzger M.B.A.
Website https://www.syndax.com
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.